Get started
Live feed
·
PRReleasevia Quantisnow
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight
Quantisnow market dataNASDAQ
Pasithea Therapeutics Corp. logo
KTTA
Pasithea Therapeutics Corp.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Listed since
2021
Get push alerts for KTTA

Follow KTTA and get a push notification the moment its next story breaks.

Full KTTA profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KTTA (Pasithea Therapeutics Corp.) and more on Quantisnow.